Trial Profile
Phase II Investigation of Adjuvant Combined Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 May 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Cisplatin
- Indications Carcinoma; Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 11 May 2023 Planned End Date changed from 1 Jul 2022 to 2 Nov 2025.
- 28 Feb 2022 Results published in the Clinical Cancer Research
- 15 Sep 2021 Planned End Date changed from 1 Jul 2021 to 1 Jul 2022.